Your browser doesn't support javascript.
loading
Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
Shen, Yingying; Zhang, Wei; Liu, Jianghua; He, Jun; Cao, Renxian; Chen, Xiguang; Peng, Xiuda; Xu, Haifan; Zhao, Qiang; Zhong, Jing; Ding, Wenjun; Lei, Xiaoyong; Jiang, Yuyang; Zu, Xuyu.
Afiliação
  • Shen Y; Institute of Clinical Medicine, The First Affiliated Hospital of University of South China, Hengyang, Hunan, China.
  • Zhang W; Department of Biology, School of Medicine, Tsinghua University, Beijing, China.
  • Liu J; Institute of Clinical Medicine, The First Affiliated Hospital of University of South China, Hengyang, Hunan, China.
  • He J; Department of Metabolism and Endocrinology, The First Affiliated Hospital of University of South China, Hengyang, Hunan, China.
  • Cao R; Department of Spine Surgery, The Affiliated Nanhua Hospital of University of South China, Hengyang, Hunan, China.
  • Chen X; Institute of Clinical Medicine, The First Affiliated Hospital of University of South China, Hengyang, Hunan, China.
  • Peng X; Department of Metabolism and Endocrinology, The First Affiliated Hospital of University of South China, Hengyang, Hunan, China.
  • Xu H; Department of Medical Oncology, The First Affiliated Hospital of University of South China, Hengyang, Hunan, China.
  • Zhao Q; Institute of Clinical Medicine, The First Affiliated Hospital of University of South China, Hengyang, Hunan, China.
  • Zhong J; Department of Thyroid Breast Surgery, The First Affiliated Hospital of University of South China, Hengyang, Hunan, China.
  • Ding W; Department of Pathology, The First Affiliated Hospital of University of South China, Hengyang, Hunan, China.
  • Lei X; Institute of Clinical Medicine, The First Affiliated Hospital of University of South China, Hengyang, Hunan, China.
  • Jiang Y; Institute of Clinical Medicine, The First Affiliated Hospital of University of South China, Hengyang, Hunan, China.
  • Zu X; Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan, China.
Int J Cancer ; 144(3): 651-664, 2019 02 01.
Article em En | MEDLINE | ID: mdl-30289981
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Quinolinas / Neoplasias de Mama Triplo Negativas Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Int J Cancer Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Quinolinas / Neoplasias de Mama Triplo Negativas Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Int J Cancer Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China